SAT-163 C-Edge Co-Star: Risk of Reinfection following Successful Therapy with Elbasvir and Grazoprevir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT)
Dore G, Altice F, Litwin A, Grebely J, Dalgard O, Gane E, Shibolet O, Luetkemeyer A, Nahass R, Peng C, Conway B, Gendrano I, Huang H, Chen E, Nguyen B, Wahl J, Barr E, Robertson M, Platt H. SAT-163 C-Edge Co-Star: Risk of Reinfection following Successful Therapy with Elbasvir and Grazoprevir in Persons who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT). Journal Of Hepatology 2016, 64: s771. DOI: 10.1016/s0168-8278(16)01503-8.Peer-Reviewed Original ResearchTHU-225 C-Edge Co-Star: Favorable Impact of Elbasvir and Grazoprevir on Health-Related Quality of Life in Treatment-Naïve HCV-Infected Persons who Inject Drugs Receiving Opioid Agonist Therapy
Arduino J, Shibolet O, Litwin A, Grebeley J, Altice F, Nwankwo C, Mast T, Jiang Z, Gendrano I, Platt H, Dore G. THU-225 C-Edge Co-Star: Favorable Impact of Elbasvir and Grazoprevir on Health-Related Quality of Life in Treatment-Naïve HCV-Infected Persons who Inject Drugs Receiving Opioid Agonist Therapy. Journal Of Hepatology 2016, 64: s403-s404. DOI: 10.1016/s0168-8278(16)00638-3.Peer-Reviewed Original Research